SeekingAlphaAugust 5, 2026 at 9:50 AM NYlast month
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo4 hours ago
Which dow jones stocks are moving on Friday?
ChartMill4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill4 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo5 hours ago
Sector Update: Financial
Yahoo6 hours ago